Edition:
United States

Aevi Genomic Medicine Inc (GNMX.OQ)

GNMX.OQ on NASDAQ Stock Exchange Global Market

1.44USD
4:00pm EDT
Change (% chg)

$0.16 (+12.50%)
Prev Close
$1.28
Open
$1.33
Day's High
$1.47
Day's Low
$1.32
Volume
148,508
Avg. Vol
173,122
52-wk High
$6.89
52-wk Low
$0.98

GNMX.OQ

Chart for GNMX.OQ

About

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $47.50
Shares Outstanding(Mil.): 37.11
Dividend: --
Yield (%): --

Financials

  GNMX.OQ Industry Sector
P/E (TTM): -- 239.63 19.01
EPS (TTM): -1.16 -- --
ROI: -124.99 -8.17 -5.03
ROE: -124.99 -11.48 -4.28

BRIEF-Adage Capital Partners report a passive stake of 5.56 pct in Aevi Genomic Medicine,

* Adage Capital Partners reports a passive stake of 5.56 pct in Aevi Genomic Medicine, as of May 24 - SEC filing Source text for Eikon: Further company coverage:

Jun 02 2017

BRIEF-Aevi Genomic Medicine posts Q1 loss per share $0.29

* Aevi Genomic Medicine announces plans to initiate Phase 2 clinical trial to confirm genetic responders to AEVI-001 and first quarter 2017 operating results

May 10 2017

BRIEF-Philip Harper reports 13.6 pct passive stake in Aevi Genomic Medicine

* Philip R. Harper reports 13.6 percent passive stake in Aevi Genomic Medicine Inc as of March 20 - sec filing Source text : http://bit.ly/2olmBsg Further company coverage:

Mar 30 2017

BRIEF-Aevi Genomic Medicine provides top-line results from saga trial

* Aevi Genomic Medicine provides top-line results from the saga trial of aevi-001

Mar 20 2017

BRIEF-Aevi Genomic Medicine reports Q4 loss per share $0.23

* Aevi Genomic Medicine reports fourth quarter and full year 2016 financial results and provides business update

Mar 09 2017

More From Around the Web

Earnings vs. Estimates